HRX 2024 AbstracX Library-Pioneering Antiarrhythmic Drug Initiation: A Patient's Journey with Software Guided Drug Dosing

Pioneering Antiarrhythmic Drug Initiation: A Patient's Journey with Software Guided Drug Dosing

Pdf Summary

The document outlines a pioneering approach in antiarrhythmic drug (AAD) initiation using software-guided dosing through the SafeBeat Rx platform, as experienced by a patient undergoing treatment. This study, supported by the National Heart, Lung, and Blood Institute, highlights advancements in drug dosing methodology facilitated by innovative technology to improve workflow efficiency in hospital settings, extend monitoring post-discharge, and enhance overall patient experience.<br /><br />The authors, Douglas Corsi, MD, Rachita Navara, MD FACC FHRS, with colleagues Aditi Pallod and Kunj Patel, MD, MSc, focus on a case study involving a 3-day inpatient dofetilide initiation using the SafeBeat Rx platform within a remote cardiac interval monitoring setup. This was facilitated by an implantable cardiac monitor (ICM) device from Boston Scientific (LUX-Dx), which allowed for simultaneous monitoring and comparison with a traditional 12-lead ECG for QTc measurement. The results demonstrated a minor difference of 11.3 ms between the ICM and traditional ECG, noting a mean absolute error (MAE) of 6.2 ms, thereby validating the close agreement and reliability between the methods.<br /><br />Key benefits of this technology include enhanced QTc measurement accuracy and prediction of the initial AAD dose, achieving a 95.6% accuracy, which falls within an acceptable range of 20 ms interobserver variability. The SafeBeat Rx technology is credited with improving healthcare outcomes for patients requiring AAD treatment through extended and efficient cardiac monitoring. Currently, the device is designated for investigational use only and not yet for sale.<br /><br />The document concludes by noting the financial interest and employment ties of Rachita Navara and Kunj Patel with SafeBeat Rx Inc., ensuring transparency in the research process.

Keywords

antiarrhythmic drug

SafeBeat Rx

software-guided dosing

cardiac monitoring

QTc measurement

implantable cardiac monitor

Boston Scientific

dofetilide initiation

healthcare outcomes

investigational use